vs
FONAR CORP（FONR）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
TransMedics Group, Inc.の直近四半期売上が大きい（$160.8M vs $25.5M、FONAR CORPの約6.3倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs 8.0%、差は57.5%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 2.4%）。TransMedics Group, Inc.の直近四半期フリーキャッシュフローが多い（$19.0M vs $-227.0K）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs -0.3%）
FONARコーポレーションは、立位型やオープン型のモデルを含む革新的なMRI装置の設計・製造・販売を専門とする医療技術企業です。主に米国の病院、画像診断センターなどを顧客とし、臨床診断向けの高精度スキャンソリューションを提供しています。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
FONR vs TMDX — 直接比較
損益計算書 — Q2 2026 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $25.5M | $160.8M |
| 純利益 | $2.1M | $105.4M |
| 粗利率 | — | 58.1% |
| 営業利益率 | 13.5% | 13.2% |
| 純利益率 | 8.0% | 65.6% |
| 売上前年比 | 2.4% | 32.2% |
| 純利益前年比 | 4.7% | 1436.9% |
| EPS（希薄化後） | — | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $25.5M | $160.8M | ||
| Q3 25 | $26.0M | $143.8M | ||
| Q2 25 | $27.3M | $157.4M | ||
| Q1 25 | $27.2M | $143.5M | ||
| Q4 24 | $24.9M | $121.6M | ||
| Q3 24 | $25.0M | $108.8M | ||
| Q2 24 | $25.9M | $114.3M | ||
| Q1 24 | $25.7M | $96.8M |
| Q4 25 | $2.1M | $105.4M | ||
| Q3 25 | $2.3M | $24.3M | ||
| Q2 25 | $729.3K | $34.9M | ||
| Q1 25 | $2.5M | $25.7M | ||
| Q4 24 | $2.0M | $6.9M | ||
| Q3 24 | $3.1M | $4.2M | ||
| Q2 24 | $830.4K | $12.2M | ||
| Q1 24 | $1.9M | $12.2M |
| Q4 25 | — | 58.1% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.4% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 59.2% | ||
| Q3 24 | — | 55.9% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 61.9% |
| Q4 25 | 13.5% | 13.2% | ||
| Q3 25 | 14.1% | 16.2% | ||
| Q2 25 | 5.3% | 23.2% | ||
| Q1 25 | 15.2% | 19.1% | ||
| Q4 24 | 11.9% | 7.1% | ||
| Q3 24 | 21.0% | 3.6% | ||
| Q2 24 | 7.4% | 10.9% | ||
| Q1 24 | 16.8% | 12.8% |
| Q4 25 | 8.0% | 65.6% | ||
| Q3 25 | 8.7% | 16.9% | ||
| Q2 25 | 2.7% | 22.2% | ||
| Q1 25 | 9.2% | 17.9% | ||
| Q4 24 | 7.9% | 5.6% | ||
| Q3 24 | 12.6% | 3.9% | ||
| Q2 24 | 3.2% | 10.7% | ||
| Q1 24 | 7.3% | 12.6% |
| Q4 25 | — | $2.59 | ||
| Q3 25 | — | $0.66 | ||
| Q2 25 | — | $0.92 | ||
| Q1 25 | — | $0.70 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $0.35 | ||
| Q1 24 | — | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $121.0K | — |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $176.9M | $473.1M |
| 総資産 | $217.2M | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $121.0K | — | ||
| Q3 25 | $122.0K | — | ||
| Q2 25 | $56.5M | — | ||
| Q1 25 | $123.0K | — | ||
| Q4 24 | $121.0K | — | ||
| Q3 24 | $136.0K | $330.1M | ||
| Q2 24 | $56.5M | $362.8M | ||
| Q1 24 | $134.0K | $350.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $66.9K | — | ||
| Q1 24 | — | — |
| Q4 25 | $176.9M | $473.1M | ||
| Q3 25 | $174.9M | $355.2M | ||
| Q2 25 | $172.6M | $318.1M | ||
| Q1 25 | $171.9M | $266.3M | ||
| Q4 24 | $169.8M | $228.6M | ||
| Q3 24 | $168.7M | $209.9M | ||
| Q2 24 | $166.0M | $189.9M | ||
| Q1 24 | $165.8M | $159.5M |
| Q4 25 | $217.2M | $1.1B | ||
| Q3 25 | $218.4M | $946.0M | ||
| Q2 25 | $216.9M | $890.5M | ||
| Q1 25 | $214.9M | $837.5M | ||
| Q4 24 | $208.0M | $804.1M | ||
| Q3 24 | $212.3M | $785.6M | ||
| Q2 24 | $214.2M | $758.6M | ||
| Q1 24 | $209.6M | $723.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $171.0K | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $-227.0K | $19.0M |
| FCFマージンFCF / 売上 | -0.9% | 11.8% |
| 設備投資強度設備投資 / 売上 | 1.6% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | 0.08× | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $5.7M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $171.0K | $34.5M | ||
| Q3 25 | $1.7M | $69.6M | ||
| Q2 25 | $4.2M | $91.6M | ||
| Q1 25 | $3.1M | $-2.9M | ||
| Q4 24 | $2.2M | $19.7M | ||
| Q3 24 | $1.7M | $6.9M | ||
| Q2 24 | $4.6M | $25.7M | ||
| Q1 24 | $2.8M | $-3.4M |
| Q4 25 | $-227.0K | $19.0M | ||
| Q3 25 | $-177.0K | $61.9M | ||
| Q2 25 | $3.6M | $82.5M | ||
| Q1 25 | $2.6M | $-29.9M | ||
| Q4 24 | $1.5M | $6.1M | ||
| Q3 24 | $-148.0K | $-41.3M | ||
| Q2 24 | $4.2M | $2.0M | ||
| Q1 24 | $2.6M | $-47.6M |
| Q4 25 | -0.9% | 11.8% | ||
| Q3 25 | -0.7% | 43.1% | ||
| Q2 25 | 13.1% | 52.4% | ||
| Q1 25 | 9.4% | -20.8% | ||
| Q4 24 | 6.0% | 5.0% | ||
| Q3 24 | -0.6% | -38.0% | ||
| Q2 24 | 16.1% | 1.7% | ||
| Q1 24 | 10.2% | -49.2% |
| Q4 25 | 1.6% | 9.7% | ||
| Q3 25 | 7.2% | 5.3% | ||
| Q2 25 | 2.4% | 5.8% | ||
| Q1 25 | 2.2% | 18.8% | ||
| Q4 24 | 3.0% | 11.2% | ||
| Q3 24 | 7.2% | 44.3% | ||
| Q2 24 | 1.6% | 20.8% | ||
| Q1 24 | 0.7% | 45.6% |
| Q4 25 | 0.08× | 0.33× | ||
| Q3 25 | 0.75× | 2.86× | ||
| Q2 25 | 5.79× | 2.62× | ||
| Q1 25 | 1.26× | -0.11× | ||
| Q4 24 | 1.14× | 2.87× | ||
| Q3 24 | 0.53× | 1.63× | ||
| Q2 24 | 5.54× | 2.11× | ||
| Q1 24 | 1.50× | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
